Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination of deramciclane and opoids as analgesics

A technology for opioids and analgesics, applied in the field of combined analgesic drug compositions, which can solve problems such as limiting therapeutic applications

Inactive Publication Date: 2007-04-11
EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENY TARSASAG
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Unfortunately, in addition to its analgesic properties, morphine also has many side effects, which limit its therapeutic application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination of deramciclane and opoids as analgesics
  • Combination of deramciclane and opoids as analgesics
  • Combination of deramciclane and opoids as analgesics

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0019] An analgesic pharmaceutical composition according to the combination of the present invention, comprising as component A) the preferred (1R,2S,4R)-(-)-2-[N,N-(dimethylaminoethoxy)]- 2-Phenyl-1,7,7-trimethylbicyclo[2.2.1]heptane-2(E)-butenedioic acid (1:1).

[0020] The combined analgesic pharmaceutical composition according to the present invention comprises as component A) the particularly preferred (1R, 2S, 4R)-(-)-2-[N,N-(dimethylamino Ethoxy)]-2-phenyl-1,7,7-trimethylbicyclo[2.2.1]heptane or a pharmaceutically acceptable acid addition salt thereof, which contains not more than 0.2% of the general formula

[0021]

[0022] (1R,3S,4R)-(-)-3-[2-N,N-(Dimethylaminoethyl)]-1,7,7-trimethylbicyclo[2.2.1]heptane -2-ketone or a pharmaceutically acceptable acid addition salt thereof.

[0023] The combined analgesic pharmaceutical composition according to the invention comprises as component A) the particularly preferred (1R,2S,4R)-(-)-2-[N,N-(dimethylaminoethoxy)] - 2-ph...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a combined analgesic pharmaceutical composition which comprises as component: A) (1R,2S,4R)-(-)-2-[N,N-(dimethylaminoethoxy)]-2-phenyl-1,7-7-trimethylbicyclo[2.2.1]heptane or a pharmaceutically acceptable acid addition salt thereof and as component B) morphine, an opioide type analgesic and / or a non-opioide type analgesic in admixture with suitable pharmaceutical carriers and / or auxiliary agents. Deramciclane increases the analgesic effect of morphine.

Description

field of invention [0001] The present invention relates to a combined analgesic pharmaceutical composition. technical background [0002] general formula [0003] [0004] (1R, 2S, 4R)-(-)-2-[N, N-(dimethylaminoethoxy)]-2-phenyl-1,7,7-trimethylbicyclo[2.2. 1] Heptane (International Nonproprietary Name: deramciclane) is an active ingredient of an anxiolytic drug which falls within the general formula of HU 179,174. The preparation of deramcyclanes is described in HU212,574. [0005] Deramciclane has been shown to be important in different animal models of anxiety and stress. Deramciclane was effective at oral doses of 1 to 10 mg / kg in the Vogel punished water test [Gacsályi et al., Receptor binding profile and anxious activity of deramciclane (EGIS-3886) in animal models, Drug Dev. Res. 40 : p.338-348, (1997)]. In the social interaction model, the compound increased the time spent in social interaction after a single oral treatment at 0.7 mg / kg. Oral single dose 3mg / ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/138A61K31/485A61P25/00A61P25/04
CPCA61K31/485A61K31/138A61P25/00A61P25/04A61P29/00A61P43/00A61K2300/00
Inventor I·加克萨尔伊G·吉格勒L·G·哈辛G·勒维G·塞纳斯
Owner EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENY TARSASAG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com